Simon Parkinson
Family · Chandler, AZNPI 1114990371
Payments from drug & device makers
Across 880 payments — averaging $45.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Ipsen Innovation$4K
- Biogen$1K
- Pfizer$972
- Jazz Pharmaceuticals Inc.$832
- Novartis$731
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$19,97650%
- Travel & lodging$3,1998%
- Food & beverage$16,56241%
- Education$4921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$18,295
- QULIPTA$5,156
- Symbravo$243
- NURTEC ODT$231
- Austedo XR$122
- ZAVZPRET$111
- VYEPTI$110
- BOTOX$102
How this compares
$40,229 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 28 | $287,613 |
| BotoxOnabotulinumtoxina | 87 | $111,009 |
| Kesimpta PenOfatumumab | 11 | $94,658 |
| Aimovig AutoinjectorErenumab-Aooe | 109 | $90,449 |
| Emgality PenGalcanezumab-Gnlm | 114 | $80,295 |
| Nurtec OdtRimegepant Sulfate | 46 | $72,578 |
| QuliptaAtogepant | 64 | $72,225 |
| UbrelvyUbrogepant | 44 | $52,088 |
| AptiomEslicarbazepine Acetate | 26 | $32,723 |
| RytaryCarbidopa/Levodopa | 26 | $24,941 |
| Emgality SyringeGalcanezumab-Gnlm | 19 | $18,012 |
| RexultiBrexpiprazole | 12 | $15,640 |
| Topiramate ErTopiramate | 14 | $10,744 |
| Gabapentin | 415 | $10,545 |
| Memantine Hcl | 430 | $8,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Qulipta, Ubrelvy | $23,627 | $235,323195 claims |
| PfizerNurtec Odt | $972 | $72,57846 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $203 | $32,72326 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $211 | $28,42157 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $215 | $15,64012 claims |
| Upsher-smith Laboratories LLCTopiramate | $119 | $2,728149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Chandler
- Mia ChorneyChandler$79K
- Anjanette KibbyChandler$21K
- Courtney BrzyckiChandler$14K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.